UPC Agreement Is Not EU Law, No Referrals to CJEU

No items found.
​
September 1, 2025

expert v. Seoul Viosys, UPC_CoA_380/2025

Order of 20 August 2025 (ORD_22147/2025)[1]

This order from the UPC Court of Appeal clearly states that the Court of Justice of the EU cannot be asked to interpret the UPC Agreement and Rules of Procedure. The order also sets out the circumstances in which a referral to the Court of Justice of the European Union (CJEU) might be made by the UPC and reiterates the need for parties to stick to the time limits specified in the Rules of Procedure.

The appeal arose from a decision of the Düsseldorf LD rejecting an application for costs by expert as inadmissible. The application for costs was brought outside the one-month time limit specified for such applications in the Rules of Procedure[2].

With its appeal, expert requested that the one-month period set out in the Rules of Procedure be extended and, as a precautionary measure, requested that the Court of Appeal refer questions to the CJEU. In essence, the requested referral was intended to resolve an alleged contradiction between the time limit imposed by the Rules of Procedure and the right of the successful party to seek reimbursement for its costs from the unsuccessful party, as set out in the UPC Agreement[3].

On its main request, expert was unsuccessful. The Court of Appeal referred to its earlier decision in Hanshow v. VusionGroup[4], where the court stated that failure to meet the one-month deadline for an application for a cost decision can only be remedied through re-establishment of rights[5], not through a retrospective extension of the deadline.

On the question of a referral, the Court of Appeal clearly stated that the CJEU cannot be asked to interpret the UPC Agreement or the Rules of Procedure. The Agreement is not a regulation, a directive, a decision, a recommendation or an opinion, nor is it an act of the institutions, bodies, offices or agencies of the Union. Indeed, the Court of Appeal considered it clear from CJEU case law that the UPC Agreement is an international agreement forming part of international law.

The Court of Appeal also considered whether the time limit specified in the Rules of Procedure is compatible with EU law. It concluded that it is, and that the correct interpretation of EU law on time limits is so obvious that it leaves no room for any reasonable doubt, making a referral to the CJEU on the compatibility of the Rule of Procedure with EU law unnecessary.

Nevertheless, the Court of Appeal set out a series of clear examples of when a referral may be appropriate:

  • When a provision of the UPCA or the RoP implements or relates to a directive, a regulation, or to an international agreement such as the Lugano Convention where the EU is a contracting party, whether the UPCA and/or the RoP make specific reference thereto or not. The EU legislation referred to in the UPCA and the RoP is not exhaustive.
  • When the UPC applies EU law.
  • When assessing the compatibility of the UPC Agreement and Rules of Procedure with EU law.

However, even in these situations, a referral will not automatically be made. So far, the UPC has not made any referrals to the CJEU, even when issues specific to EU law come up, as in Aylo v. Dish[6]. In that case, the court was asked but declined to refer a question to the CJEU regarding jurisdiction and the application of the Brussels I recast regulation.

The present order sets out very clearly that referrals will not be made to the CJEU for the purpose of interpreting the UPC Agreement or Rules of Procedure. This means that referrals to the CJEU are likely to be rare in practice, only arising when there is a question of EU law or when the compatibility of the UPC Agreement or Rules of Procedure with EU law is unclear.

[1] https://www.unifiedpatentcourt.org/en/node/137181

[2] Rule 151 RoP: "Where the successful party… wishes to seek a cost decision, it shall within one month of service of the decision lodge an Application for a cost decision…"

[3] Article 69 UPCA: "Reasonable and proportionate legal costs and other expenses incurred by the successful party shall, as a general rule, be borne by the unsuccessful party…"

[4] https://www.unifiedpatentcourt.org/en/node/125743, UPC_CoA_618/2024, decision of 6 June 2025 (ORD_69091/2024)

[5] Rule 320 RoP: "Where a party has failed to observe a time-limit set by these Rules or the Court for a cause which, despite all due care having been taken by the party…"

[6] UPC_CoA_188/2024, order of 3rd September 2024 ORD_42716/2024, as reported here: https://eip.com/uk/latest/article/upc_court_of_appeal_clarifies_jurisdiction_on_indirect_infringement/

The Latest Thought Leadership pieces in the Content Hub

UPC Considers but does not decide exhaustion of rights in relation to consumables
October 30, 2025
Brita v. Aquashield UPC CFI 248/2024 (Munich LD), decision of 22 August 2025[1] UPC CFI 564/2024 (Munich LD), decision of 16 October 2025[2] Brita sued Aquashield and others for infringement of...
UPC takes strict approach on costs reimbursement
October 30, 2025
Insulet v. EOFlow UPC_CFI_773/2025 and UPC_CFI 774/2025 (Milan CD), decision of 15 October 2025[1] The dispute began when Insulet sought a provisional injunction against EOFlow to prevent...
Unconventional Service: igus v. Whale Technology
August 29, 2025
UPC_CFI_318/2025, decision of 5 August 2025 (ORD_34299/2025)[1] In a default judgment issued by the Düsseldorf Local Division of the Unified Patent Court, Whale Technology (Shanghai) Co., Ltd.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
The UPC After Three Years: From Experiment to Enforcement Forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
Inside the Visser AI Launch Party
20 May 2026
EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.
Protecting Your Startup: Five Intellectual Property Mistakes to Avoid
20 May 2026
Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.
Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.